CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma Market Outlook

Thelansis’s “CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma Overview

CAR T-cell therapy represents a promising breakthrough in treating Diffuse Large B-cell Lymphoma (DLBCL) patients. This malignancy has historically posed challenges in achieving long-term remission. Typically, patients with DLBCL respond to initial chemotherapy containing anthracycline and rituximab with an overall response rate of approximately 60%. However, the long-term event-free survival rate is only 50%, indicating a significant relapse or treatment failure risk. Unfortunately, for a substantial portion of patients, approximately 30% to 40%, relapse occurs despite receiving intensive salvage chemotherapy that may incorporate monoclonal antibodies such as rituximab or ofatumumab, as well as autologous stem cell transplantation (ASCT). The outcomes are frequently unfavorable in these cases, with an overall response rate ranging from 27% to 63% and long-term survival rates reaching up to 48%. Additionally, a significant challenge arises in only 50% of relapsed patients being eligible for ASCT due to inadequate responses to salvage chemotherapy or issues with stem cell collection. However, the advent of CAR T-cell therapy brings newfound hope for patients with multiply relapsed DLBCL, a population for whom durable remission and cure were previously improbable. CAR T-cell therapy involves genetically modifying a patient’s T cells to recognize and target cancer cells more effectively, bolstering the immune system’s ability to fight the lymphoma. Given its remarkable potential, CAR T-cell therapy is now emerging as a compelling second-line treatment option for suitable patients with refractory or early relapsing DLBCL. The therapy’s ability to achieve durable remission and even potential cures makes it a promising candidate for becoming the new standard of care in this setting.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: CAR T-Cell Therapy Opportunity within Diffuse Large B-Cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034